Affigen develops tumor-identifying therapies to treat cancer. By utilizing precision design, we can drive powerful immune responses against molecules unique to cancer, while minimizing the risk of damage to healthy tissues. To do this, we focus on highly-automated process engineering and personal-scale biologics manufacturing in order to develop new therapies for previously “undruggable” targets. In effect, we focus on cancer’s “Achille’s Heel”: the proteins which distinguish tumor cells from normal cells, which can target tumor cells for destruction with extreme sensitivity and precision. As a translational-stage company, we develop our therapeutics with rapid clinical adoption in mind, and in close collaboration with an extensive expert network of world-class academic collaborators.
|HQ||St. Louis, US||Map|
|Employees (est.) (May 2020)||2|
Affigen total Funding
Affigen latest funding size
Time since last funding
|3 years ago|
|Black Beret Life Sciences|
When was Affigen founded?
Affigen was founded in 2016.
Who are Affigen key executives?
Affigen's key executives are Carlos Santos, Jonathan Feldmann and David States.
How many employees does Affigen have?
Affigen has 2 employees.
Who are Affigen competitors?
Competitors of Affigen include Arcus Biosciences, OncBioMune Pharmaceuticals and Replimune.
Where is Affigen headquarters?
Affigen headquarters is located at 20 S Sarah St, St. Louis.
Where are Affigen offices?
Affigen has offices in St. Louis and Austin.
How many offices does Affigen have?
Affigen has 2 offices.
Receive alerts for 300+ data fields across thousands of companies